MedTrace Logo

Study of the Vector Vaccine GamCovidVac-M (Altered Antigenic Composition)

NCT06068556 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-10-05

No results posted yet for this study

Summary

Safety, reactogenicity and immunogenicity study of the vector vaccine GamCovidVac-M for the prevention of coronavirus (COVID-19) infection caused by the SARS-CoV-2 virus with altered antigenic composition with participation of 12-17 years old volunteers.

Conditions

Interventions

BIOLOGICAL

GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition

Two intramuscular injections of GamCovidVac-M vector vaccine for the prevention of COVID-19 with altered antigenic composition will be performed. 1st injection - component I, 2nd injection - component II.

Sponsors & Collaborators

  • Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

    lead OTHER

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-31
Primary Completion
2024-12-31
Completion
2024-12-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06068556 on ClinicalTrials.gov